Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
Giordano Botta, CEO and Co-Founder of Allelica, shared a post on LinkedIn:
“We are proud to partner with the U.S. Department of Veterans Affairs, the largest integrated healthcare system in the United States, on a randomized clinical trial evaluating the impact of polygenic risk score (PRS) and pharmacogenomics (PGx) in routine care.
This comes at a pivotal moment, as the new 2026 ACC/AHA guidelines now include PRS as a risk enhancing factor.
The study will compare standard care with a genomic guided approach.
Patients in the intervention arm will receive the Allelica multi-ancestry PRS for coronary artery disease together with PGx testing for statin response, including SLCO1B1.
The objective is to assess whether integrating genetic risk and drug response can improve statin prescription, adherence, and ultimately cardiovascular outcomes.
We look forward to supporting this clinical trial, designed to generate prospective evidence on the clinical utility of integrating PRS and PGx into cardiovascular prevention, with the potential to inform implementation at scale across large healthcare systems.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 13:39Amr Saad: What Tips You Toward Cerebral Venous Thrombosis Over IIH?
-
Aug 14, 2026, 13:28Eduardo Medronha: DIPS as a Rescue Strategy in Budd–Chiari Syndrome
-
Aug 14, 2026, 13:18Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank